Drugs / JTK-853
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01473056 | Aug → Oct 2010 | hepatitis C virus infection | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01473069 | Mar → Jul 2010 | — | Akros Pharma Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01475981 | Jan → Apr 2010 | — | Akros Pharma Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTK-853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01475981 ↗ |
| Modality | Small molecule | — CHEMBL4297295 ↗ |
| Route | Oral | “single oral doses of JTK-853” NCT01475981 ↗ |